Ryan Tarzy
CEO
Avandra provides source‑level access to real‑world medical imaging data by integrating directly with health systems' PACS and VNAs, delivering validated, provenance‑tracked datasets that are secure and compliant. The platform’s expert‑guided curation assembles custom imaging collections ready for analysis, supporting standardized metrics, longitudinal studies, and multi‑modal correlation with clinical or molecular data for pharmaceutical, biotech, and AI research.
Raised to date
$17.8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.


Pharmaceutical and AI researchers often lack direct, high-quality access to real-world medical imaging data because imaging repositories are siloed within health systems’ PACS and VNAs, leading to noisy, incomplete datasets and extensive effort to locate relevant studies.
Avandra provides source-level access to imaging data directly from health systems’ PACS and VNAs, delivering validated, compliant, and provenance‑tracked datasets. The platform curates millions of studies with expert guidance, ensuring each pixel and data point is accurate and representative. Researchers receive bespoke imaging collections that are ready for analysis, enabling standardized metrics, longitudinal assessments, and correlation with clinical or molecular data. By keeping data in place and handling secure transfer, Avandra eliminates blind searches, reduces bias, and accelerates drug development and AI model validation.
Primary customers are pharmaceutical companies, biotech firms, and AI/ML developers that require high‑quality real‑world imaging data for clinical trials, regulatory submissions, and algorithm training.